Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mesoblast Limited ( (AU:MSB) ) has provided an update.
Mesoblast reported gross revenue of US$35.1 million from Ryoncil sales in the quarter ended 31 December 2025, a 60% increase over the prior quarter, underscoring rapid uptake of the first FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft-versus-host disease. Supported by a new US$125 million, five-year interest-only facility from its largest shareholder that refinanced more expensive debt and released key assets from security interests, the company has strengthened its balance sheet and lowered its cost of capital, positioning it to pursue strategic partnerships, expand Ryoncil into the larger adult SR-aGvHD market and other inflammatory indications, and continue development of its broader pipeline.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is a biotechnology company specializing in allogeneic, off-the-shelf cellular medicines for severe and life-threatening inflammatory conditions. Its lead product, Ryoncil (remestemcel-L-rknd), is the first FDA-approved mesenchymal stromal cell therapy and the only approved treatment in the U.S. for children under 12 with steroid-refractory acute graft-versus-host disease, while additional candidates such as rexlemestrocel-L target heart failure and chronic low back pain. The company leverages a broad intellectual property portfolio extending to at least 2044, proprietary large-scale manufacturing, and commercial partnerships across Japan, Europe and China to advance its mesenchymal lineage cell therapy platforms in major global markets.
Average Trading Volume: 4,009,094
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$3.51B
For detailed information about MSB stock, go to TipRanks’ Stock Analysis page.